The increase in price target by Wells Fargo suggests a positive outlook on Acelyrin's stock, potentially leading to increased investor confidence and a short-term rise in stock price. The Equal-Weight rating indicates that the stock is expected to perform in line with the sector or the overall market, but the raised target price signals an improved valuation of the company's prospects.